Sarcopenia in elderly diabetes

Wen, Chen‐Yu; Lien, Angela Shin‐Yu; Jiang, Yi

doi:10.1111/jdi.13752

Cited by 11 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, our study proposed an easily accessible parameter for screening sarcopenia in elderly patients with diabetes, which may facilitate the prevention and treatment of sarcopenia in people with diabetes. Recently, sarcopenia has been implicated as both a cause and consequence of diabetes 9 10. However, there is insufficient evidence for treatment recommendations for patients with diabetes with sarcopenia, including nutritional supplements, dietary advice and planned exercise 9.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Association between serum triglyceride to high-density lipoprotein cholesterol ratio and sarcopenia among elderly patients with diabetes: a secondary data analysis of the China Health and Retirement Longitudinal Study

Lin,

Zhong,

Sun

2023

BMJ Open

View full text Add to dashboard Cite

ObjectivePrevious studies investigating the association between the serum triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio and the occurrence of sarcopenia in different populations have yielded inconsistent results. This study aimed to investigate the potential association between TG/HDL-C ratio and sarcopenia among elderly Chinese patients with diabetes.DesignA secondary data analysis.SettingThis was a secondary analysis of data from the China Health and Retirement Longitudinal Study.ParticipantsIn this study, 752 elderly individuals with diabetes were included after excluding individuals aged <60 years old, those with missing data for the assessment of sarcopenia and missing measurements for plasma glucose or glycated haemoglobin.Outcome measuresThe primary information included TG/HDL-C ratio, muscle strength, physical performance, muscle mass and covariables. The association between TG/HDL-C ratio and sarcopenia was assessed using ordinal logistic regression and linear regression analysis.ResultsOn multivariate ordinal logistic regression, among male patients, compared with those with the lowest quartile of TG/HDL-C ratio (≤1.41), those with the highest quartile (>4.71) had a significantly lower risk of more severe sarcopenia (OR 0.24, 95% CI 0.10 to 0.54). Similarly, among female patients, compared with those with the lowest quartile of TG/HDL-C ratio (≤2.07), those with the highest quartile (>5.61) had a significantly lower risk of more severe sarcopenia (OR 0.17, 95% CI 0.07 to 0.44). In multivariate linear regression, male patients with the highest quartile of TG/HDL-C ratio (β=0.36, 95% CI 0.20 to 0.51) had higher muscle mass than those with the lowest quartile. Similarly, female patients with the highest quartile of TG/HDL-C ratio (β=0.31, 95% CI 0.10 to 0.51) had higher muscle mass than those with the lowest quartile.ConclusionsThere was a negative association between TG/HDL-C ratio categorised by quartile and sarcopenia, which indicates that a higher TG/HDL-C ratio may be related to better muscle status.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Diabetes mellitus and sarcopenia have a bidirectional relationship 9 10. In elderly patients with diabetes, decline in exercise capacity has been recognised as a new complication 11.…”

Section: Introductionmentioning

confidence: 99%

Association between serum triglyceride to high-density lipoprotein cholesterol ratio and sarcopenia among elderly patients with diabetes: a secondary data analysis of the China Health and Retirement Longitudinal Study

Lin,

Zhong,

Sun

2023

BMJ Open

View full text Add to dashboard Cite

show abstract

“…Sarcopenia is prevalent in diabetes, especially in the elderly [ 17 ], and is associated with increased mortality in patients with T2DM [ 18 ]. Impaired insulin signaling is an underlying cause of sarcopenia in diabetes [ 19 , 20 ].…”

Section: Introductionmentioning

confidence: 99%

Ketogenic diet preserves muscle mass and strength in a mouse model of type 2 diabetes

Park,

Yang

2024

PLoS ONE

View full text Add to dashboard Cite

Diabetes is often associated with reduced muscle mass and function. The ketogenic diet (KD) may improve muscle mass and function via the induction of nutritional ketosis. To test whether the KD is able to preserve muscle mass and strength in a mouse model of type 2 diabetes (T2DM), C57BL/6J mice were assigned to lean control, diabetes control, and KD groups. The mice were fed a standard diet (10% kcal from fat) or a high-fat diet (HFD) (60% kcal from fat). The diabetic condition was induced by a single injection of streptozotocin (STZ; 100 mg/kg) and nicotinamide (NAM; 120 mg/kg) into HFD-fed mice. After 8-week HFD feeding, the KD (90% kcal from fat) was fed to the KD group for the following 6 weeks. After the 14-week experimental period, an oral glucose tolerance test and grip strength test were conducted. Type 2 diabetic condition induced by HFD feeding and STZ/NAM injection resulted in reduced muscle mass and grip strength, and smaller muscle fiber areas. The KD nutritional intervention improved these effects. Additionally, the KD altered the gene expression of nucleotide-binding and oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome- and endoplasmic reticulum (ER) stress-related markers in the muscles of diabetic mice. Collectively, KD improved muscle mass and function with alterations in NLRP3 inflammasome and ER stress.

show abstract

“… 13 It is estimated that the prevalence of sarcopenia will increase significantly within the next 30 years, 14 becoming a major public issue. Sarcopenia and T2DM have a bidirectional relationship, 15 increase the risk of each other 16 and lead to functional decline and disability. 17 Recent studies have shown that patients with T2DM and sarcopenia have a higher mortality rate than those without sarcopenia.…”

Section: Introductionmentioning

confidence: 99%

The Association Between Sarcopenia and Diabetes: From Pathophysiology Mechanism to Therapeutic Strategy

Hui-ling¹,

Huang²,

Dong³

et al. 2023

DMSO

View full text Add to dashboard Cite

Diabetes and sarcopenia are emerging as serious public health issues. Sarcopenia, an age-related disorder characterized by loss of skeletal muscle mass and function, is recognized as a new complication in elderly patients with type 2 diabetes mellitus (T2DM). Type 2 diabetes is characterized by insulin resistance, chronic inflammation, accumulation of advanced glycation products and increased oxidative stress, which can negatively affect skeletal muscle mass, strength and function leading to sarcopenia. There is a mutual interrelationship between T2DM and sarcopenia in light of pathophysiology mechanism and long-term outcome. T2DM will accelerate the decline of muscle mass and function, which will in turn lead to glucose metabolism disorders, reduced physical activity and the risk of diabetes. However, the specific mechanism involved has not been thoroughly studied. Therefore, this review aims to explore the pathophysiology and therapeutic strategy related to sarcopenia and diabetes and provide insight for future investigations, which is of great significance for improving the quality of life in the elderly with diabetes and concurrently reducing the incidence of related complications.

show abstract

Sarcopenia in elderly diabetes

Cited by 11 publications

References 25 publications

Association between serum triglyceride to high-density lipoprotein cholesterol ratio and sarcopenia among elderly patients with diabetes: a secondary data analysis of the China Health and Retirement Longitudinal Study

Association between serum triglyceride to high-density lipoprotein cholesterol ratio and sarcopenia among elderly patients with diabetes: a secondary data analysis of the China Health and Retirement Longitudinal Study

Ketogenic diet preserves muscle mass and strength in a mouse model of type 2 diabetes

The Association Between Sarcopenia and Diabetes: From Pathophysiology Mechanism to Therapeutic Strategy

Contact Info

Product

Resources

About